<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688606</url>
  </required_header>
  <id_info>
    <org_study_id>2020108</org_study_id>
    <nct_id>NCT04688606</nct_id>
  </id_info>
  <brief_title>Circulating Tumor Cell Capture for Early Diagnosis and Postoperative Tumor Recurrence Monitoring of Liver Cancer</brief_title>
  <official_title>Zhongnan Hospital of Wuhan University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongnan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongnan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through the screening of CTCs in patients with suspected liver cancer and liver tumor&#xD;
      resection or liver transplantation, the number of CTCs in the blood of liver cancer patients&#xD;
      before and after surgery is monitored, and the clinical application significance of CTCs in&#xD;
      liver cancer screening and postoperative recurrence monitoring in liver cancer patients is&#xD;
      evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Screen patients with suspected liver cancer Long-term exposure to liver cancer risk&#xD;
           factors (hepatitis B carriers, past history of schistosomiasis, long-term diet of&#xD;
           Aspergillus food, history of liver cirrhosis, etc.), patients with liver cancer are&#xD;
           initially suspected.&#xD;
&#xD;
        2. Monitor the number of CTCs in the blood of patients with liver cancer before and after&#xD;
           surgery Imaging examinations show that liver space is occupied by patients with&#xD;
           suspected liver cancer. Use CTCBIOPSY® technology to monitor patients' surgical&#xD;
           operations (including interventional therapy, tumor resection, or liver cancer liver&#xD;
           transplantation) at different times 1-3 days before, 1 month after surgery, and 6 months&#xD;
           after surgery The number of CTCs in peripheral blood.&#xD;
&#xD;
        3. To evaluate the clinical application significance of CTCs in liver cancer screening and&#xD;
           postoperative recurrence monitoring in patients with liver cancer Combined with&#xD;
           clinicopathology, tumor marker examination and imaging examination, clinical follow-up&#xD;
           and follow-up, analyze the clinical significance of CTCs detection in liver cancer&#xD;
           patients, and focus on evaluating the relationship between circulating tumor cells in&#xD;
           liver cancer screening and postoperative recurrence, and establish a new The liver&#xD;
           cancer prediction model improves the prognosis of liver cancer patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">May 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical detection of circulating tumor cells</measure>
    <time_frame>2020.01.20-2021.02.28</time_frame>
    <description>To evaluate the specificity of CTCs for liver cancer screening and the feasibility of early recurrence after interventional therapy, tumor resection or liver transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulating tumor cell function detection and verification</measure>
    <time_frame>2020.03.01-2021.05.20</time_frame>
    <description>Analyze the correlation between circulating tumor cells and clinical prognosis after liver cancer surgery and further mechanism exploration</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Circulating Tumor Cell</condition>
  <arm_group>
    <arm_group_label>Two groups</arm_group_label>
    <description>Initial diagnosis of suspected hepatocellular carcinoma;&#xD;
patients undergoing liver transplantation, radical resection or ablation of liver cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Circulating tumor cell capture technology</intervention_name>
    <description>CTCBIOPSY® automatic testing platform</description>
    <arm_group_label>Two groups</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. Primary diagnosis of suspected hepatocellular carcinoma; or liver cancer patients who&#xD;
             have undergone liver transplantation, radical resection or ablation of liver cancer;&#xD;
&#xD;
          2. Age 18-75 years old;&#xD;
&#xD;
          3. ASA (risk of anesthesia) score I-II;&#xD;
&#xD;
          4. The ECOG score is 0-1;&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary diagnosis of suspected hepatocellular carcinoma; or liver cancer patients who&#xD;
             have undergone liver transplantation, radical resection or ablation of liver cancer;&#xD;
&#xD;
          2. Age 18-75 years old;&#xD;
&#xD;
          3. ASA (risk of anesthesia) score I-II;&#xD;
&#xD;
          4. The ECOG score is 0-1;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In addition to hepatocellular carcinoma, patients diagnosed with other types of&#xD;
             tumors;&#xD;
&#xD;
          2. Patients with extrahepatic or lymphatic metastasis;&#xD;
&#xD;
          3. Patients who still have serious complications 4 weeks after surgery;&#xD;
&#xD;
          4. Patients who cannot provide informed consent;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifa Ye</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qifa Ye</last_name>
    <phone>+86-02767812988</phone>
    <email>190679136@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenjin Liang</last_name>
    <phone>+86-02767812988</phone>
    <email>190679136@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qifa Ye</last_name>
      <phone>+86-02767812988</phone>
      <email>190679136@qq.com</email>
    </contact>
    <investigator>
      <last_name>Qifa Ye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating tumor cells, hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

